Musk Says Blindsight Device to Restore Vision Is Engineering-Ready
Technology
Elon Musk says Blindsight, a Neuralink device intended to restore visual perception in blind people, is ready from an engineering standpoint. He says it could help even people who have never seen, but its deployment depends on regulatory approval.
The entrepreneur announced the product in a post on the social media platform X. “Our second product is called Blindsight and it will, as the name suggests, enable even those who are completely blind or have never seen to see. It is ready from an engineering standpoint. Just waiting on regulatory approval,” Musk wrote.
Blindsight is being developed by Neuralink, a company working on brain-computer interface technology. According to the company’s description, the visual prosthesis is designed to capture images with a camera and transmit information to the brain through an implant that stimulates areas associated with vision. The approach is intended to bypass the natural pathway that carries signals from the eyes to the brain. However, a statement that the technology is engineering-ready does not mean its effectiveness has been demonstrated in clinical trials.
In September 2024, Neuralink announced that the U.S. Food and Drug Administration (FDA) had granted Blindsight Breakthrough Device Designation, a status for promising medical devices. The designation can support faster development and priority review, but it is not, by itself, authorization to market or use the device.
Neuralink’s website says the company plans to inform interested people about future U.S. clinical trials of its visual prosthesis. At the time of Musk’s announcement, Blindsight was still awaiting the necessary regulatory approval. The post did not specify when trials might begin or when the device could enter practical use.
Blindsight therefore remains a technology under development, rather than an available treatment for blindness. The project’s stated aim is to make visual perception possible for people with severe vision loss, including those who have been blind since birth. The device’s actual capabilities will need to be assessed through further research and regulatory review.
Blindsight is being developed by Neuralink, a company working on brain-computer interface technology. According to the company’s description, the visual prosthesis is designed to capture images with a camera and transmit information to the brain through an implant that stimulates areas associated with vision. The approach is intended to bypass the natural pathway that carries signals from the eyes to the brain. However, a statement that the technology is engineering-ready does not mean its effectiveness has been demonstrated in clinical trials.
In September 2024, Neuralink announced that the U.S. Food and Drug Administration (FDA) had granted Blindsight Breakthrough Device Designation, a status for promising medical devices. The designation can support faster development and priority review, but it is not, by itself, authorization to market or use the device.
Neuralink’s website says the company plans to inform interested people about future U.S. clinical trials of its visual prosthesis. At the time of Musk’s announcement, Blindsight was still awaiting the necessary regulatory approval. The post did not specify when trials might begin or when the device could enter practical use.
Blindsight therefore remains a technology under development, rather than an available treatment for blindness. The project’s stated aim is to make visual perception possible for people with severe vision loss, including those who have been blind since birth. The device’s actual capabilities will need to be assessed through further research and regulatory review.
Powered by Froala Editor